Optimised dalbavancin for serious bacterial infections
This study tests a better way to give a long-acting antibiotic called dalbavancin for serious bacterial infections. Dalbavancin is given as an infusion and may allow you to leave the hospital sooner while still completing your antibiotic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are in the hospital for a serious bacterial infection that can be cured with a limited course of antibiotics (about 4-6 weeks).
- You are already receiving effective antibiotics for at least 24 hours and up to 14 days.
- Your doctor plans to prescribe dalbavancin as part of your regular care.
- You are able to give written consent and attend follow-up visits.
- You do not have severe kidney problems, severe liver disease, or a history of allergy to dalbavancin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibiotic called oritavancin for treating serious heart infections caused by certain bacteria. It may offer a simpler treatment option for patients who are already on antibiotics and stable.
This trial tests whether dalbavancin (an antibiotic given as a dose or doses) works as well as standard antibiotics to treat bloodstream infections related to a removed IV catheter caused by Staphylococcus aureus. It may help reduce treatment time and dosing complexity if you qualify.
This study looks back at patients who received the antibiotic dalbavancin as a long-term suppressive therapy for stubborn infections. It aims to see how well it worked and if it was safe.
This study tests a new antibiotic called dalbavancin for treating infections of the heart valves. It may offer a simpler treatment option with fewer hospital visits.
This trial tests whether an antibiotic called dalbavancin, given to prevent bacterial infections during chemotherapy-induced low white blood cell counts, is safe and works in children and young adults with certain types of leukemia. It may help reduce the risk of serious infections during treatment.
This study tests whether a new antibiotic (BV100) combined with other antibiotics works safely and effectively against serious infections caused by drug-resistant Acinetobacter bacteria. It may offer a treatment option when standard antibiotics are not working.
Hear when a new Serious Gram-Positive Bacterial Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.